Technical Analysis for OMER - Omeros Corporation

Grade Last Price % Change Price Change
grade D 15.47 -0.32% -0.05
OMER closed down 0.32 percent on Wednesday, October 23, 2019, on 49 percent of normal volume.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Weak or Absent Down Down Flat
See historical OMER trend table...

Date Alert Name Type % Chg
20 DMA Resistance Bearish 0.00%
Evening Star Bearish -0.32%
Fell Below 20 DMA Bearish -0.32%
Crossed Above 20 DMA Bullish -3.07%
Up 3 Days in a Row Strength -3.07%
MACD Bullish Signal Line Cross Bullish -2.46%
Shooting Star Candlestick Bearish 0.72%
180 Bearish Setup Bearish Swing Setup 0.72%
Doji - Bearish? Reversal 0.72%
Oversold Stochastic Weakness 0.72%

Older signals for OMER ...

Get a Trading Assistant

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:
Profile
Omeros Corporation, a clinical-stage biopharmaceutical company, engages in discovering, developing, and commercializing products targeting inflammation, coagulopathies, and disorders of the central nervous system. The company derives product candidates from its proprietary PharmacoSurgery platform that is designed to enhance clinical outcomes of patients undergoing ophthalmological, arthroscopic, urological, and other surgical and medical procedures. The company's product candidates include OMS302, which has completed two Phase III clinical trials for use during intraocular lens replacement surgery, including cataract and other lens replacement surgery; OMS103HP that is in Phase III program for use during arthroscopic procedures comprising partial meniscectomy surgery; and OMS201, which has completed Phase I/Phase II studies for use during urological procedures, including ureterscopy for removal of ureteral or renal stones. Its clinical programs also consist of OMS824, which is in Phase I clinical trial for the treatment of cognitive disorders, including schizophrenia; and OMS405 that is in Phase II clinical trial for the treatment and prevention of addiction to substances of abuse. The company's preclinical product development programs comprise OMS721 for hemolytic uremic syndrome, paroxysmal nocturnal hemoglobinuria, wet age-related macular degeneration, ischemia-reperfusion injury, and transplant-related complications; OMS527 for addictions and compulsive disorders, and movement disorders; and OMS616 for surgical and traumatic bleeding. In addition, it is developing G protein-coupled receptors (GPCR) programs for multiple disorders. Omeros Corporation was incorporated in 1994 and is based in Seattle, Washington.
Medicine Biopharmaceutical Health Medical Specialties Surgery Inflammation Clinical Trial Disorders Schizophrenia Ophthalmology Clinical Research Wet Age Related Macular Degeneration Movement Disorders Urology Cataract Paroxysmal Nocturnal Hemoglobinuria Surgical Specialties Cognitive Disorders Arthroscopy Hemolytic Uremic Syndrome
Is OMER a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 0 bullish, 3 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 20.92
52 Week Low 10.3
Average Volume 389,338
200-Day Moving Average 16.5626
50-Day Moving Average 17.5518
20-Day Moving Average 15.6675
10-Day Moving Average 15.44
Average True Range 0.6613
ADX 23.12
+DI 17.2637
-DI 24.4361
Chandelier Exit (Long, 3 ATRs ) 16.2061
Chandelier Exit (Short, 3 ATRs ) 16.5839
Upper Bollinger Band 16.5727
Lower Bollinger Band 14.7623
Percent B (%b) 0.39
BandWidth 11.55513
MACD Line -0.5124
MACD Signal Line -0.6106
MACD Histogram 0.0982
Fundamentals Value
Market Cap 693.1 Million
Num Shares 44.8 Million
EPS -1.47
Price-to-Earnings (P/E) Ratio -10.52
Price-to-Sales 11.55
Price-to-Book 0.00
PEG Ratio -0.13
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 16.04
Resistance 3 (R3) 16.05 15.88 15.95
Resistance 2 (R2) 15.88 15.73 15.87 15.91
Resistance 1 (R1) 15.67 15.64 15.59 15.66 15.88
Pivot Point 15.50 15.50 15.45 15.49 15.50
Support 1 (S1) 15.29 15.35 15.21 15.28 15.06
Support 2 (S2) 15.12 15.26 15.11 15.03
Support 3 (S3) 14.91 15.12 15.00
Support 4 (S4) 14.90